




RealRate

PHARMACEUTICAL 2016

Talpheria INC
Rank 216 of 295

AcelRx
Pharmaceuticals, Inc.



The relative strengths and weaknesses of Talpheria INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Talpheria INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 40% points. The greatest weakness of Talpheria INC is the variable Other Liabilities, reducing the Economic Capital Ratio by 113% points.

The company's Economic Capital Ratio, given in the ranking table, is 182%, being 81% points below the market average of 263%.

Input Variable	Value in 1000 USD
Assets, Current	118,947
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	12,780
Liabilities, Non-Current	16,381
Other Assets	228
Other Compr. Net Income	3.0
Other Expenses	3,286
Other Liabilities	65,511
Other Net Income	-3,685
Other Revenues	19,263
Property and Equipment	8,610
Research and Development	22,488
Selling, General and Administrative Expense	14,203

Output Variable	Value in 1000 USD
Assets	127,785
Liabilities	94,672
Expenses	39,977
Revenues	19,263
Stockholders Equity	33,113
Net Income	-24,399
Comprehensive Net Income	-24,398
BaseVar	142,692
ECR before LimitedLiability	43%
Economic Capital Ratio	182%